Phase I, randomized, double blind, placebo-controlled, dose-finding trial. The trial´s goal is to evaluate two different doses of Bryostatin on HIV-1 latency and reservoir in HIV-1 infected patients receiving antiretroviral treatment.

Inclusion Criteria:

• Patients understanding the trial purpose
• Patients between 18 and 50 years of age
• Patients with chronic HIV-1 infection
• Patients receiving antiretroviral treatment with at least 3 active drugs for at least 2 years
• Undetectable viral load measured by ultra sensitive methods
• CD4+ levels higher than 350 cells/mm3
• Patients committed to use contraceptive methods during the trial and up to 3 months after.

Exclusion Criteria:

• Previous antiretroviral treatment failure, as any viral load outbreak after having had undetectable HIV-1 load. Low grade, transitory outbreaks (<200 RNA copies/ml) resolved without treatment modifications are excluded
• Patients planned to interrupt antiretroviral treatment during the trial
• Patients receiving immunosuppressant or immunostimulant drugs, including valproic acid.
• Pregnant women
• Bryostatin-1 hypersensitivity
• Being enrolled in another clinical trial or having participated in another clinical trial in the previous 3 months.